Zobrazeno 1 - 10
of 242
pro vyhledávání: '"Tamura A"'
Autor:
Tomohide Tamura, Kazumasa Noda, Shinzoh Kudoh, José Baselga, Johan Vansteenkiste, Giuseppe Giaccone, Seiji Yano, Takeshi Horai, Kazuhiko Nakagawa, Ichiro Takata, Rui Ping Dong, Masahiro Fukuoka, Egbert F. Smit, Jean-Yves Douillard, Danny Rischin, Richard Eek, A. Feyereislova, Steven D. Averbuch, Yutaka Nishiwaki, Angela Macleod
Publikováno v:
Journal of Clinical Oncology. 41:1162-1171
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non–small-cell lung
Autor:
Junji Tsurutani, Caleb Lee, Ian E. Krop, Shunji Takahashi, Rashmi Krishna Murthy, Alvaro Moreno-Aspitia, Javad Shahidi, Masahiro Sugihara, Haeseong Park, Yasuaki Sagara, Kenji Tamura, Lin Zhang, Charles H. Redfern, Yoshihiko Fujisaki, Hiroji Iwata, Shanu Modi, Toshihiko Doi
Publikováno v:
Journal of Clinical Oncology. 38:1887-1896
PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evalua
Autor:
Shun-ichi Kimura, Jun Yamanouchi, Kazuo Tamura, Shingen Nakamura, Hiroki Yamaguchi, Yoshinobu Kanda, Akinao Okamoto, Yasushi Takamatsu, Tatsuo Oyake, Masaki Iino, Yoshio Saburi, Hiroyuki Fujita, Yumi Jo, Emiko Sakaida, Moritaka Gotoh, Shin-ichiro Fujiwara, Takahiro Fukuda, Itaru Matsumura, Souichi Shiratori
Publikováno v:
Journal of Clinical Oncology. 38:815-822
PURPOSE Empiric antifungal therapy (EAT) is recommended for persistent febrile neutropenia (FN), but in most patients, it is associated with overtreatment. The D-index, calculated as the area surrounded by the neutrophil curve and the horizontal line
Autor:
Michiaki Kubo, Toshimi Takano, Naoto T. Ueno, Kan Yonemori, Akira Kitani, Reiki Nishimura, Yasuhiro Fujiwara, Masato Takahashi, Shigehira Saji, Taisei Mushiroda, Chiyo K. Imamura, Kazuhiko Sato, Yusuke Tanigawara, Kenji Tamura, Junji Tsurutani, Takeharu Yamanaka
Publikováno v:
Journal of Clinical Oncology. 38:558-566
PURPOSE In patients taking tamoxifen, the CYP2D6 genotype causes different exposure of active metabolite endoxifen. The objective of this randomized, open-label, multicenter, phase II study was to prospectively evaluate whether CYP2D6 genotype–guid
Autor:
Yuji Shibata, Shingo Matsumoto, Shunta Mori, Tetsuya Sakai, Hiroki Izumi, Hibiki Udagawa, Kaname Nosaki, Yoshitaka Zenke, Kiyotaka Yoh, Haruko Daga, Atsuhisa Tamura, Jun Sakakibara-Konishi, Shoichi Kuyama, Naoki Furuya, Atsushi Nakamura, Masato Shingyoji, Kazumi Nishino, Terufumi Kato, Susumu Kobayashi, Koichi Goto
Publikováno v:
Journal of Clinical Oncology. 40:9103-9103
9103 Background: Osimertinib is a standard drug for first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations (mt). While tumor mutational burden (TMB)-high and co-occurring genetic alterations (alt)
Autor:
Christy Cho, Ralph H. Hruban, P. Dane Witmer, Jin He, Thomas Barkley, Jose Alejandro Almario, Anne Macgregor-Das, Alison P. Klein, Koji Shindo, Madeline Ford, Matthew J. Weiss, Tae Jun Song, Abdulrehman Siddiqui, Jun Yu, Christopher L. Wolfgang, Nicholas J. Roberts, Aaron Brant, Michael Goggins, Shahriar Fesharakizadeh, Michael Borges, Koji Tamura, Masaya Suenaga
Publikováno v:
Journal of Clinical Oncology. 35:3382-3390
Purpose Deleterious germline mutations contribute to pancreatic cancer susceptibility and are well documented in families in which multiple members have had pancreatic cancer. Methods To define the prevalence of these germline mutations in patients w
Autor:
Natalia Fadeeva, Martin Reck, Tomohide Tamura, Jacek Jassem, Aleksandra Szczesna, Myung-Ju Ahn, Ramaswamy Govindan, Pieter E. Postmus, Takayasu Kurata, Baohui Han, Joachim von Pawel, Vladimir Vladimirov, Justin Kopit, Kenneth J. O'Byrne, Fabrice Barlesi, Pablo González Mella, Mingshun Li, Doina Elena Ganea, Li Zhang, Ki Hyeong Lee, Marina Tschaika, Claus Peter Schneider
Publikováno v:
Journal of Clinical Oncology. 35:3449-3457
Purpose Patients with squamous non–small-cell lung cancer (NSCLC) have poor prognosis and limited treatment options. This randomized, double-blind, phase III study investigated the efficacy and safety of first-line ipilimumab or placebo plus paclit
Autor:
Caleb Lee, Junji Tsurutani, Shunji Takahashi, Kenji Tamura, Javad Shahidi, Ian E. Krop, Lin Zhang, Toshihiko Doi, Haeseong Park, Yoshihiko Fujisaki, Rashmi Krishna Murthy, Alvaro Moreno-Aspitia, Masahiro Sugihara, Yasuaki Sagara, Shanu Modi, Hiroji Iwata, Charles H. Redfern
Publikováno v:
Journal of Clinical Oncology. 38:3351-3352
Autor:
Kazumasa Fujitani, Hisato Kawakami, Naotoshi Sugimoto, Masahiro Goto, Taroh Satoh, Daisuke Sakai, Toshimasa Tsujinaka, Shunji Endo, Jin Matsuyama, Yusuke Akamaru, Youichi Makari, Toshio Shimokawa, Yutaka Kimura, Takao Tamura, Shigeyuki Tamura, Yukinori Kurokawa
Publikováno v:
Journal of Clinical Oncology. 38:379-379
379 Background: HERBIS-2 trial was a phase II trial where S-1 plus cisplatin (SP) and capecitabine plus cisplatin (XP) were compared in recurrent HER2 negative gastric cancer (GC) patients with recurrence free interval (RFI) by S-1containing adjuvant
Autor:
Kenichi Inoue, Kazuo Matsuura, Junji Tsurutani, Toshiaki Saeki, Tetsuhiko Taira, Yuko Tanabe, Tomohide Tamura, Kaoru Kubota
Publikováno v:
Journal of Clinical Oncology. 39:12094-12094
12094 Background: Fosnetupitant (FN) is a phosphorylated pro-drug of netupitant that has high binding affinity and selectivity for the neurokinin 1 receptor and a long half-life of 70 h. Recent studies have reported that fosaprepitant (FA) has a risk